Vallverdú-Prats Marta, Alcalde Mireia, Sarquella-Brugada Georgia, Cesar Sergi, Arbelo Elena, Fernandez-Falgueras Anna, Coll Mónica, Pérez-Serra Alexandra, Puigmulé Marta, Iglesias Anna, Fiol Victoria, Ferrer-Costa Carles, Olmo Bernat Del, Picó Ferran, Lopez Laura, Jordà Paloma, García-Álvarez Ana, Llano Coloma Tirón de, Toro Rocío, Grassi Simone, Oliva Antonio, Brugada Josep, Brugada Ramon, Campuzano Oscar
Cardiovascular Genetics Center, University of Girona-IdIBGi, Girona 17190, Spain.
Centro Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid 28029, Spain.
J Pers Med. 2021 Feb 26;11(3):162. doi: 10.3390/jpm11030162.
Genetic interpretation of rare variants associated with arrhythmogenic cardiomyopathy (ACM) is essential due to their diagnostic implications. New data may relabel previous variant classifications, but how often reanalysis is necessary remains undefined. Five years ago, 39 rare ACM-related variants were identified in patients with features of cardiomyopathy. These variants were classified following the American College of Medical Genetics and Genomics' guidelines. In the present study, we reevaluated these rare variants including novel available data. All cases carried one rare variant classified as being of ambiguous significance (82.05%) or likely pathogenic (17.95%) in 2016. In our comprehensive reanalysis, the classification of 30.77% of these variants changed, mainly due to updated global frequencies. As in 2016, nowadays most variants were classified as having an uncertain role (64.1%), but the proportion of variants with an uncertain role was significantly decreased (17.95%). The percentage of rare variants classified as potentially deleterious increased from 17.95% to 23.07%. Moreover, 83.33% of reclassified variants gained certainty. We propose that periodic genetic reanalysis of all rare variants associated with arrhythmogenic cardiomyopathy should be undertaken at least once every five years. Defining the roles of rare variants may help clinicians obtain a definite diagnosis.
由于其诊断意义,对与致心律失常性心肌病(ACM)相关的罕见变异进行基因解读至关重要。新数据可能会重新标记先前的变异分类,但重新分析的频率仍不明确。五年前,在具有心肌病特征的患者中鉴定出39种与ACM相关的罕见变异。这些变异根据美国医学遗传学与基因组学学会的指南进行分类。在本研究中,我们重新评估了这些罕见变异,包括新获得的数据。在2016年,所有病例均携带一种被分类为意义不明确(82.05%)或可能致病(17.95%)的罕见变异。在我们的全面重新分析中,这些变异中有30.77%的分类发生了变化,主要是由于全球频率的更新。与2016年一样,如今大多数变异被分类为作用不确定(64.1%),但作用不确定的变异比例显著下降(17.95%)。被分类为潜在有害的罕见变异比例从17.95%增加到23.07%。此外,83.33%的重新分类变异获得了明确的分类。我们建议,应至少每五年对所有与致心律失常性心肌病相关的罕见变异进行一次定期基因重新分析。明确罕见变异的作用可能有助于临床医生做出明确诊断。